# A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

> **NCT05132582** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 654 (actual)

## Conditions studied

- HER2 Positive Breast Cancer

## Interventions

- **DRUG:** Tucatinib
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Combination product: Trastuzumab + Pertuzumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05132582
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-07
- **Primary completion:** 2025-09-05
- **Final completion:** 2027-09-28
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132582, "A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05132582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*